Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
BioSpace49m
Higher Biopharma M&A Activity ‘Almost Inevitable’ in 2025, With Viking as Top Candidate: Analysts
Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...
As demand for weight-loss drugs rises, states grapple with Medicaid coverage
Ozempic was originally approved to treat people with Type 2 diabetes, but demand has surged because of the drug’s weight-loss ...
Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
Walla Walla Union Bulletin6dOpinion
Commentary: The bar for successful obesity drugs is rising
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
Why the Obesity Drug Revolution Is a Work in Progress
A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...
Price must be right to put obesity pill on the PBS
Whether to fully subsidise the new generation weight loss drugs such as Mounjaro and Ozempic for obese Australians without ...
Opinion
Medicare should cover anti-obesity drugs
The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.
Pharmaceutical Technology11h
Bivamelagon by Rhythm Pharmaceuticals for Obesity: Likelihood of Approval
Bivamelagon is under clinical development by Rhythm Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate ...
Tirzepatide outpacing Wegovy in the obesity space
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
Pharmaceutical Technology11h
BG-102 by SL Bigen for Obesity: Likelihood of Approval
BG-102 is under clinical development by SL Bigen and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication ...